A Phase I Study of EZN-3042, a Novel Survivin Messenger Ribonucleic Acid (mRNA) Antagonist, Administered in Combination With Chemotherapy in Children With Relapsed Acute Lymphoblastic Leukemia (ALL)Elizabeth A. Raetz, William L. Carroll, D. Morrison et al.|Journal of Pediatric Hematology/Oncology|2013Cited by 41
A Phase I Dose Finding Study of Panobinostat in Children with Hematologic Malignancies: Initial Report of TACL Study T2009-012 in Children with Acute LeukemiaJohn M. Goldberg, Julio C. Barredo, Jessica A. Pollard et al.|Blood|2014Cited by 11